Lexaria Bioscience Corp. develops and licenses DehydraTECH, a patented oral drug delivery formulation and processing platform designed to improve how active pharmaceutical ingredients enter the bloodstream. News about LEXX centers on GLP-1 drug delivery research, DehydraTECH-semaglutide compositions, preclinical and human study updates, intellectual property activity, and pharmaceutical partner evaluations under material transfer arrangements.
Company updates also cover Lexaria's investor communications, oral drug delivery market commentary, and applications of DehydraTECH across pharmaceuticals, nutraceuticals, over-the-counter products, and consumer formats. Recurring themes include bioabsorption, tolerability, blood-brain-barrier delivery, research laboratory activity, and the company's IP licensing business model.
Lexaria (NASDAQ:LEXX) highlights rapid growth in the oral GLP-1 pill market and potential demand for its DehydraTECH delivery platform. Key industry signals include 600,000 Wegovy pill prescriptions in the first two months and analyst GLP-1 forecasts ranging up to $180B by mid-2030s. Lexaria reports DehydraTECH performance with semaglutide, tirzepatide, and liraglutide and plans 2026 R&D to explore retatrutide and amycretin applicability while engaging pharmaceutical partners.
Lexaria Bioscience (NASDAQ:LEXX) has contracted a CRO to run its 2026 animal Study #1 (GLP-1-A26-1) to test DehydraTECH-semaglutide and DehydraTECH-CBD formulations and pursue new intellectual property claims.
The study plans 8–11 arms in Sprague-Dawley rats, blood sampling over an 8–24-hour post-dose window, brain biodistribution measures, reference arms, dosing targeted to begin in approximately 60 days, and is fully funded from existing corporate resources.
Lexaria (Nasdaq:LEXX) applauded the FDA approval of Eli Lilly's oral GLP-1 drug Foundayo for adult weight control on April 7, 2026. Lexaria highlights expanding oral GLP-1 choices (now three brands) and cites Foundayo's 72-week average weight loss of 27.3 lb (12.4%).
Lexaria notes DehydraTECH has shown side-effect reductions (Study GLP-1-H24-4: 47.9% fewer adverse events vs Rybelsus) and holds 65 issued patents, with additional GLP-1 testing planned in 2026.
Lexaria (NASDAQ:LEXX) signed contracts with a CRO to run Human Pilot Study #7 (GLP-1-H26-7) evaluating two oral DehydraTECH-semaglutide (DHT-sema) formulations versus Wegovy tablets.
The 5-week, three-arm parallel study will test tablet and capsule DHT-sema with SNAC under fasted conditions, aiming to assess safety, tolerability and pharmacokinetics; ethics approval is pending and the study is fully funded from corporate resources.
Lexaria (Nasdaq:LEXX) announced five new patents across Japan and Australia, expanding its IP for hypertension, epilepsy and diabetes treatments tied to its DehydraTECH delivery platform.
New grants: two Japan hypertension patents (issued Feb 20, 2026; term to Apr 25, 2043), one Australian epilepsy patent (issued Feb 12, 2026; term to Feb 20, 2044), and two Australian diabetes patents (issued Feb 12, 2026; term to Dec 3, 2044). Lexaria cites a Phase 1b human study that supported DehydraTECH combined with GLP-1 drugs.
Lexaria (NASDAQ:LEXX) outlines its strategy to develop oral GLP-1 capsule and tablet alternatives using its patented DehydraTECH platform, citing intellectual property established in 2024–2025 and early-stage commercial discussions with several multinational pharmaceutical companies. The company highlights market forecasts suggesting oral GLP-1s could represent a $40–45 billion annual market within four years and cites patient tolerability and discontinuation rates as drivers for its program.
Lexaria (Nasdaq:LEXX) announced its 2026 R&D Program launching a 5-week human study and two large animal studies to advance oral GLP-1 drug delivery and IP development.
The human study (GLP-1-H26-7) targets safety, tolerability and PK versus Wegovy tablets, with ~30 subjects per tablet arm and 15 in the capsule arm; recruitment may begin in April and a final report is expected in Q4 2026. Two animal studies (GLP-1-A26-1 and GLP-1-A26-2) with multiple arms (8–11 and 14–18 respectively) are planned to start in Q2 2026 with reports near end of Q3 2026. Work aims to generate new formulations, brain biodistribution data, and potential patentable IP to support pharma partnerships.
Lexaria (NASDAQ:LEXX) announced final results from Human Pilot Study #5 comparing oral DehydraTECH-liraglutide (DHT-LIR) capsules to injected Saxenda® (SAX-LIR) liraglutide. The Study met its primary safety and tolerability endpoint, reporting a 22.7% reduction in adverse events with DHT-LIR, including 67% less nausea and 31% fewer GI adverse events.
Pharmacokinetic blood quantitation faced assay background noise challenges, limiting PK conclusions to exploratory ELISA signal visualizations that showed broadly similar temporal patterns between treatments. Lexaria is exploring a 505(b)(2) regulatory pathway and potential collaborations to develop an oral liraglutide product.
Lexaria (Nasdaq:LEXX) announced six newly granted patents, bringing its total to 60 granted patents across major global markets as of January 22, 2026.
The six grants include: Australia (first patent) for Family #20 (sublingual nicotine); EU (first patent) for Family #21 (hypertension); two Australia and one EU patents for Family #24 (epilepsy); and one new US patent for Family #27 (diabetes), bringing that family to two US patents.
Shareholders are reminded to vote at the Annual Meeting on January 27, 2026 at 1:00 PM PT.
Lexaria (Nasdaq:LEXX) CEO published the company's 2025 annual letter on January 12, 2026, summarizing R&D, clinical, patent and financing progress. Key facts: Lexaria completed a Phase 1b registrational study in Australia with primary endpoints met and a 48% reduction in total adverse events for the DHT-semaglutide arm versus Rybelsus®; earlier pilot studies showed 47% AE reduction for DHT-tirzepatide and 23% AE reduction for DHT-liraglutide. Lexaria also completed a rodent biodistribution study showing higher brain signal for DHT-processed semaglutide, was granted 10 patents (totaling 56 worldwide), extended an MTA with a pharma partner through April 30, 2026, and raised $9.5M in 2025.